Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer

International Journal of Gynecological Cancer

Volumn 21, Issue 8, 2011, Pages 1446-1451

  Di Legge, Alessia ^a   Trivellizzi, Ilaria Nausica ^a   Moruzzi, Maria Cristina ^a   Pesce, Adele ^a   Scambia, Giovanni ^a   Lorusso, Domenica ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Chemotherapy; Myocet; Recurrent endometrial cancer

Indexed keywords

CARBOPLATIN; DOXORUBICIN; PACLITAXEL; ANTINEOPLASTIC ANTIBIOTIC;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CONSTIPATION; DISEASE ACTIVITY; DISEASE DURATION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; ELECTROCARDIOGRAPHY; ENDOMETRIUM CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAIR LOSS; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; INFECTION; LIVER DISEASE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PERITONEUM METASTASIS; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CARCINOMA; CLINICAL TRIAL; ENDOMETRIUM TUMOR; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; TREATMENT FAILURE; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT FAILURE;

EID: 84857496764     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31822d754e     Document Type: Article

References (27)

1. Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, et al. Current issues in the management of endometrial cancer. Mayo Clinic Proc. 2008;83:97-112.
2. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006;24:36-44. (Pubitemid 46630491)
3. Hogberg T, Signorelli M, Freire de Oliveira C, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - results from two randomised studies. Eur J Cancer. 2010;46:2422-2431.
4. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004;15:1173-1178. (Pubitemid 39199303)
5. Muggia FM, Blessing JA, Sorosky J, et al. Phase II trial of pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2002;20:2360-2364. (Pubitemid 34441664)
6. Dizon DS, Blessing JA, McMeekin DS, et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129-P. J Clin Oncol. 2009;27:3104-3108.
7. Wadler S, Levy DE, Lincoln ST, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group study E3E93. J Clin Oncol. 2003;21:2110-2114. (Pubitemid 46606359)
8. Thigpen JT, Blessing JA, Lagasse LD, et al. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol. 1984;7:253-256. (Pubitemid 14112252)
9. Burke TW, Munkarah A, Kavanagh JJ, et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol. 1993;51:397-400.
10. Sutton GP, Blessing JA, Demars LR, et al. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol. 1996;63:25-27. (Pubitemid 26337960)
11. Lincoln S, Blessing JA, Lee RB, et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:277-281. (Pubitemid 36335809)
12. Garcia AA, Blessing JA, Nolte S, et al. Gynecologic Oncology Group. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol Oncol. 2008;111:22-26.
13. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736-1744. (Pubitemid 29269242)
14. Rose PG, Blessing JA, Lewandowski GS, et al. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;63:101-104. (Pubitemid 26337974)
15. Gehrig PA, Bae-Jump VL, et al. Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol. 2010;116:187-194.
16. Escobar PF, Markman M, Zanotti K, et al. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J Cancer Res Clin Oncol. 2003;129:651-654. (Pubitemid 37452631)
17. Pignata S, Scambia G, Pisano C, et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007;96:1639-1643. (Pubitemid 46847208)
18. du Bois A, Pfisterer J, Burchardi N, et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol. 2007;107:518-525. (Pubitemid 350160867)
19. Swenson CE, Bolcsak LE, Batist G, et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs. 2003;14:239-246. (Pubitemid 36418944)
20. Kaplan HG, Malmgren JA, Atwood M, et al. Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/ polysomy 17 absent breast cancer patients. Cancer Manag Res. 2010;2:213-218.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
22. National Cancer Institute. Common Toxicity Criteria, Version 4.0. National Cancer Institute; 2010.
23. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10. (Pubitemid 19099520)
24. Chen TT, Ng TH. Optimal flexible designs in phase II clinical trials. Stat Med. 1998;17:2301-2312. (Pubitemid 28482675)
25. Sorbe B, Andersson H, Boman K, et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel - long-term follow-up. Int J Gynecol Cancer. 2008;18:803-808. (Pubitemid 352020182)
26. Angioli R, Palaia I, Calcagno M, et al. Liposome-encapsulated doxorubicin citrate in previously treated recurrent/metastatic gynecological malignancies. Int J Gynecol Cancer. 2007;17:88-93. (Pubitemid 46213975)
27. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25-36. (Pubitemid 34049039)